New Insights in Design and Development of Antitubercular Drugs

(E-pub Abstract Ahead of Print)

Author(s): Snehlata Yadav, Balasubramanian Narsimhan*.

Journal Name: Current Bioactive Compounds

Submit Manuscript
Submit Proposal


According to the World Health Organization, tuberculosis, caused mainly by the Mycobacterium tuberculosis, is the infectious disease that accounts for the highest number of deaths worldwide. Despite curing millions, the currently used drug regimens are bounded by various limitations such as long course of therapy, emergence of resistance and permanent tissue damage. The treatment of multidrug-resistant and extremely drug-resistant tuberculosis is challenging as it basically relies on second-line drugs that are less potent and more toxic than those used in the clinical management of drug-susceptible tuberculosis. Therefore, the major challenges in the coming years are to overcome the emergence of increased number of multidrug-resistant as well as extensively drug-resistant strains and the ineptness of the current treatment regimens against latent tuberculosis. Bedaquiline and Delamanid are the only new anti-TB drugs that have been currently approved since more than 40 years after discovery of isoniazid. Bedaquiline is a first-in-class diarylquinoline derivative that showed durable culture conversion at 24 weeks in phase IIb trials. In this review, we have focused on the different classes of compounds with potent antitubercular activity against multidrug-resistant tuberculosis strains along with plant based antitubercular agents. The vaccine and peptide-based conjugates has been developed recently against Mycobacterium for selective and specific targeting of the drugs to the desired tissues.

Keywords: Admantane, isocitrate lyase, conjugate, vaccine, therapy, pharmacophore

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Abstract Ahead of Print)
DOI: 10.2174/1573407215666190409153756
Price: $95